AFP
ADAP

Ausdal Financial Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Ausdal Financial Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,476
Closed -$2.99K – 934
2025
Q2 		$2.99K Hold
12,476
– – ﹤0.01% 690
2025
Q1 		$2.46K Buy
+12,476
New +$6.46K ﹤0.01% 644

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Ausdal Financial Partners's ADAP Position: Q3 2025 in Review

Ausdal Financial Partners sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 12,476 shares — an estimated $2.99K sold.

Ausdal Financial Partners first reported a position in ADAP in Q1 2025 and held it in 2 quarters. The position peaked at $2.99K in Q2 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • Ausdal Financial Partners reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ausdal Financial Partners sold 12,476 Adaptimmune Therapeutics shares in Q3 2025, an estimated $2.99K.
  • Ausdal Financial Partners first reported a position in Adaptimmune Therapeutics in Q1 2025 and held it in 2 quarters.
  • Ausdal Financial Partners's Adaptimmune Therapeutics position peaked at $2.99K in Q2 2025.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Ausdal Financial Partners's 13F filing for Q3 2025, filed 14 Nov 2025.